Abstract
Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%.
As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.
Keywords: Severe Colitis, Corticosteroids, Cyclosporine, Infliximab, Colectomy, Sigmoidoscopy
Current Drug Targets
Title: Acute Severe Colitis: Infliximab and/or Cyclosporine?
Volume: 12 Issue: 10
Author(s): Mauro Fabro, Hajnalka Szabo, Giovanni Terrosu, Claudio Avellini, Maria Tabuso, Gionata Fiorino and Dario Sorrentino
Affiliation:
Keywords: Severe Colitis, Corticosteroids, Cyclosporine, Infliximab, Colectomy, Sigmoidoscopy
Abstract: Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%.
As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.
Export Options
About this article
Cite this article as:
Fabro Mauro, Szabo Hajnalka, Terrosu Giovanni, Avellini Claudio, Tabuso Maria, Fiorino Gionata and Sorrentino Dario, Acute Severe Colitis: Infliximab and/or Cyclosporine?, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818234
DOI https://dx.doi.org/10.2174/138945011796818234 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Resident Kidney Cells and Their Involvement in Glomerulonephritis
Current Drug Targets - Inflammation & Allergy Probing Cerebrovascular Alterations in Alzheimers Disease Using MRI: From Transgenic Models to Patients
Current Medical Imaging New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Physiological Changes in the Critically Ill Patient with Sepsis
Current Pharmaceutical Biotechnology Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Current Medicinal Chemistry Cell Death Targets and Potential Modulators in Alzheimers Disease
Current Pharmaceutical Design Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Pattern of Primary Vasculitis with Peripheral Ischemic Manifestations: Report of a Case Series and Role of Vascular Surgery
Current Rheumatology Reviews